Evicenter
MarkdownMedical informationP&T meetings
Ifezuntirgene inilparvovec (AMT-130)

Huntington's disease

Manufacturer
uniQure
Launch
Not announced
Last updated
291 sources

Clinical evidence

CT-AMT-130-02

32 evidence topics · 11 sources

Objective
Location and study date
Study sites and dates in the ClinicalTrials.gov record
FieldRegistry value
Site, Warsaw, Poland“Instytut Psychiatrii i Neurologii”
Site, Warsaw, Poland“Interventional Neuro Center”
Site, Cardiff, United Kingdom“Cardiff University”
Site, London, United Kingdom“National Hospital for Neurology & Neurosurgery”
Study start (actual)“2021-10-07”
Primary completion (estimated)“2029-03”
Study completion (estimated)“2029-10-07”
EU trial record after transition to the Clinical Trials Regulation
FieldRecord value
Protocol code“CT-AMT-130-02”
Transition trial“Yes”
Locations“Poland”
Start of trial“Start of trial 07/10/2021”
Current status in Poland“Ongoing, recruitment ended”
Recruitment end in Poland“15/10/2024”
Estimated global end date“31/12/2029”
Study design
Trial design fields in the EU Clinical Trials Register
FieldRegister value
Controlled“No”
Randomised“No”
Open“Yes”
Double blind“No”
Eligibility criteria
Treatment
Investigational product concentration in the EU Clinical Trials Register
Study outcomes
Rationale for using safety measures as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
FieldRegistry value
Enrollment (actual)“14”
Description of analysis sets

No evidence found.

Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Safety notifications in the EU trial record
NotificationRecord value
Serious breach“Serious Breach (0)”
Unexpected event“Unexpected Event (0)”
Urgent safety measure“Urgent Safety Measure (0)”
Temporary halt“Temporary Halt (0)”
Study limitations
Summary
  • Open-label, uncontrolled design with inconsistent records: the EU Clinical Trials Register lists the trial as not controlled, not randomised, open, and not double blind. The ClinicalTrials.gov record describes open-label Cohorts 1 and 2 and randomization in Cohort 3 only, lists allocation as randomized and masking as none (open label), and gives an official title describing a randomized, double-blind study; version 1 (2022) listed a non-randomized, open-label design with an estimated enrollment of 15.
  • Enrollment: 15 participants were planned (six low dose, nine high dose). The Form 10-K reports 13 participants enrolled and treated (six low dose, seven high dose), while the ClinicalTrials.gov record lists an actual enrollment of 14.
  • Sites: the February 2022 release named sites in Poland, the United Kingdom, and Germany; the ClinicalTrials.gov record lists sites in Poland and the United Kingdom, and the CTIS record lists Poland.
  • Results reporting: the pooled-analysis protocols pool data across the U.S. and EU studies, and the registered primary outcomes are safety and tolerability measures, including adverse events.
  • Safety: suspected unexpected severe adverse reactions occurred in two high-dose participants treated at a single clinical site.